Expression of vitamin D receptor in lung cancer

Ulrich Kaiser(University of Applied Sciences Landshut), K. Havemann(Philipps University of Marburg), Jürgen Hofmann(Philipps University of Marburg), B. Wegmann(Philipps University of Marburg), Saskia Wedel(Goethe University Frankfurt), M. Schilli(Philipps University of Marburg), P. Barth(Philipps University of Marburg)
Journal of Cancer Research and Clinical Oncology
June 1, 1996
10.1007/bf01220803
Cited by 14

Related Papers

Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
|New England Journal of Medicine|2013|3.3k
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
|The Lancet|2013|1.5k
Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial
|The Lancet Oncology|2015|402
Incidence and risk factors of central nervous system recurrence in aggressive lymphoma—a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL)
|Annals of Oncology|2006|280
<i>CEBPA</i> mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome
|Blood|2021|170